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Primary Cutaneous T-Cell Lymphomas Do not Show
Specific NAV3 Gene Deletion or Translocation
Marion Marty1,2,5, Martina Prochazkova1,5, Elodie Laharanne1, Edith Chevret1, Michel Longy3,
Thomas Jouary4, Be´atrice Vergier1,2, Marie Beylot-Barry1,3 and Merlio Jean Philippe1,2
The mapping of a balanced t(12;18)(q21;q21.2) translocation in a Se´zary syndrome (SS) case led Karenko et al. to
identify NAV3 gene (12q21–22) deletion by interphase fluorescence in situ hybridization (FISH) in 15/21 patients
with mycosis fungoides (MF) or SS. To determine whether the NAV3 deletion is the result of a specific gene
breakpoint, we used FISH with dual-color split or break-apart bacterial artificial chromosome (BAC) probes
covering the NAV3 locus. A total of 31 samples (18 skin, 11 blood, 1 lymph node, and 1 spleen) from 24 patients
with advanced MF/SS (18 with large-cell transformation) were studied. Chromosome 12 imbalances were
analyzed by comparative genomic hybridization (CGH) array with a 3K BAC probes in 24 samples from 22
patients. Both normal FISH and CGH array patterns were observed in 22 samples from 18 patients. In 6 patients,
abnormal patterns were observed with an abnormal number of chromosome 12 set in 5 of them. Chromosome
12 structural abnormalities were seen in four of these six patients. An imbalanced FISH pattern between NAV3
and pericentromeric control probes was seen in three patients in accordance with CGH array data (one with a
pericentromeric deletion and two with a large 12q deletion including NAV3). No NAV3 specific breakpoint or
partial deletion was detected.
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INTRODUCTION
Mycosis fungoides (MF) and Se´zary syndrome (SS) are the
most common forms of cutaneous T-cell lymphoma (CTCL),
accounting for almost 50% of all cutaneous lymphoma
(Willemze et al., 2005). In most patients, MF is, over years or
decades, an indolent epidermotropic CTCL with cutaneous
patches or plaques. At such early (IA–IIA) tumor node
metastasis (TNM) stages (Bunn and Lamberg, 1979; Olsen
et al., 2007), superficial dermal and intraepidermal neo-
plastic T cells do not account for more than 10% of the skin
cell population. At advanced stages (IIB–IVB), tumor cells
become predominant and epidermotropism may be lost
(Willemze et al., 2005). Transformation into skin tumors with
dense dermal infiltrates and more than 25% of large cells
is a characteristic feature of transformed MF (T-MF)
(Diamandidou et al., 1998; Vergier et al., 2000). Transforma-
tion only occurs in about 20% of patients with MF but has a
poor prognosis with extracutaneous spread and a median
survival of 1–2 years (Siegel et al., 2000).
In contrast to MF, SS arise as an aggressive leukemic
variant of epidermotropic CTCL historically defined by a triad
of erythroderma, generalized lymphadenopathy, and the
presence of neoplastic T cells in skin, lymph node, and
peripheral blood. Therefore, patients with SS present de novo
with an advanced TNM stage. Although typical MF and SS
present as separate diseases, their clinicopathological fea-
tures may associate or overlap with erythrodermic MF cases,
leukemic spreading in MF patients, or large-cell transforma-
tion at the blood level and/or skin tumors in patients with SS
(D’Alessandro et al., 1992; Prochazkova et al., 2005).
Indeed, peripheral blood was initially found informative for
the detection of cytogenetic aberrations in patients with either
SS or advanced stage MF (Thangavelu et al., 1997; Karenko
et al., 1999, 2003). In either blood or skin samples, the number
of chromosomal abnormalities identified by conventional
cytogenetics, multicolor fluorescent in situ hybridization
(FISH), or comparative genomic hybridization (CGH) was
found to correlate with TNM stage of patients with either MF or
SS, favoring the hypothesis of a common oncogenesis
(Thangavelu et al., 1997; Mao et al., 2002; Karenko et al.,
2003; Fischer et al., 2004). Despite extensive research, the
observation of recurrent translocations in some CTCL cases
was not reproducible between series and no cytogenetic
hallmark of epidermotropic CTCL has been identified (Mao
et al., 2003; Fischer et al., 2004; Prochazkova et al., 2007).
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In 2005, a leader group in CTCL cytogenetics provided
evidence that this ‘‘holy grail’’ quest was about to be
achieved (Karenko et al., 2005). Using multicolor FISH on
peripheral blood samples in seven patients with SS and
five patients with MF, clonal deletions or translocations
with a breakpoint in 12q21 or 12q22 were observed in
five of seven consecutive SS, whereas non-clonal abnormal-
ities of chromosome 12 were observed in MF cases. The
breakpoint was further mapped by locus-specific FISH in one
SS patient with a balanced translocation t(12;18)(q21;q21.2)
and shown to disrupt the NAV3 gene, the human UNC-53
homolog.
Only one missense mutation was found in the micro-
scopically intact allele of blood cells in one out of six SS
patients with the 12q cytogenetic aberration. Thus, NAV3
gene monoallelic translocation/deletion or chromosome
12 monosomy was suggested to account for NAV3 haploin-
sufficiency and underexpression as observed by immuno-
histochemistry. Locus-specific FISH with two adjacent bacter-
ial artificial chromosome (BAC) probes covering the 30 part of
the NAV3 gene (exons 10–40) and a chromosome 12
centromere probe showed NAV3 deletion in solid tissue
samples of 4 out of 8 patients with early MF (50%) and 11
of 13 patients with advanced MF/SS (85%) (Karenko et al.,
2005).
The aim of our study was to reproduce the above data on
an independent series using the same probe set covering the
NAV3 gene locus. We also aimed to determine whether
NAV3 deletions are the result of a larger chromosome 12
deletion or associated with a specific breakpoint of one
NAV3 allele. Therefore, we developed a split signal or break-
apart dual-color DNA probe FISH assay on cytogenetic
preparations and/or on interphase nuclei. To minimize false
negative results, we selected a set of samples with abundant
tumor cell content (more than 50%) in patients with
advanced MF/SS for which NAV3 gene deletions should be
expected at a very high rate. Chromosome 12 imbalances
were also analyzed by CGH array in 24 samples from 22
patients.
RESULTS
Patients and samples
To minimize false negative results, the study included 24
patients with advanced epidermotropic CTCL. There were 17
males and 7 females (mean age 72 years), and their main
clinical features (duration of the disease and prior treatment)
are summarized in Table 1.
Clinicopathological diagnosis and TNM staging corre-
sponded to the time of biological sampling according to
updated criteria (Olsen et al., 2007). Patients presented with
either de novo SS (n¼ 4), T-MF alone (n¼13), transformed SS
(n¼4) (1 preceded by MF), or secondary SS (n¼3) (2
associated with T-MF and 1 preceded by MF). Interestingly, 7
patients (cases 9, 12, 18, 21–24) did not receive any specific
therapy, and sampling was performed at the time or shortly
after diagnosis. Totally, 31 biological samples were obtained
from skin (n¼18), blood (n¼11), lymph node (n¼1), and
spleen (n¼1), and 44 experimental samples were analyzed
according to the type of preparation (cell culture, imprints,
isolated nuclei).
FISH analysis
Conventional cytogenetic preparations were obtained
from 11 blood samples and 3 skin samples. The low
background of FISH assay on such preparations allowed
simultaneous triple hybridization of DEAC (Blue) 30NAV3
probes together with Spectrum Green pericentromeric 12p
and Spectrum Red 50NAV3 probes (Figure 1a). Interpretation
was performed both on metaphases and interphase nuclei as
shown by the visualization of Spectrum Green pericentro-
meric 12p and Spectrum Red 50NAV3 probe signals (Figures
2a and c) and the DEAC 30NAV3 probe signals (Figures 2b
and d). Normal diploid cases were characterized by a 2:2:2
ratio between 50NAV3/30NAV3 and 12p control probes.
Hybridization with dual-color 50NAV3 and 30NAV3 split
DNA probes always provided 1, 2, 3, or 4 fusion (F) patterns
according to the number of NAV3 alleles. No split or partial
NAV3 deletion was observed, as shown by an identical value
for 50NAV3/12p and 30NAV3/12p ratios, as indicated in
Table 1.
Imprints were obtained from frozen tissues (11 skin 1
spleen), whereas nuclei preparation was obtained from 7 skin
and 1 lymph node biopsies. Such preparations were analyzed
by three consecutive rounds of dual-color dual-probe
hybridization (Figure 1b). As shown in Table 2 and Table
S1, the determination of 50NAV3/12p and 30NAV3/12p ratios
provided concordant results both for normal and abnormal
cases. Such ratios also correlated with the number of NAV3
fusion signals provided by dual hybridization of 50NAV3/
30NAV3 probes. Indeed, a break-apart/split signal or partial
50NAV3 or 30NAV3 loss was never observed. Interestingly,
the same skin samples of patients 3, 6, and 18 gave similar
results, irrespective of whether they were studied by triple
hybridization on cytogenetic preparation or by three con-
secutive dual hybridizations on nuclei preparation (data not
shown).
Altogether, 22 samples in 18 patients (cases 7–24)
exhibited a normal disomic or diploid profile with the
12 pericentromeric probe without NAV3 breakpoint or
deletion (Table S1). Nine samples from six patients (cases
1–6) were found to exhibit chromosome 12 numerical and/or
structural alterations (Table 2). Abnormal number of chromo-
some 12 set with balanced ratios between the 12p
pericentromeric and 50NAV3 and 30NAV3 probes was
observed for samples 1, 2, 3b, and 5 corresponding to either
chromosome 12 trisomy or tetrasomy. For example, a
numerical gain in chromosome 12 signals was observed in
about 76% of nuclei in skin sample 3b from case 3 (Figures
2c and d). Abnormal number of chromosome 12 set with
imbalanced ratios was observed for samples 4a and 4b
corresponding to chromosome 12 tetrasomy in a hypotetra-
ploid subclone (32–58% of nuclei) together with the loss
of one NAV3 fusion signal. Hemizygous loss of NAV3
fusion signals was detected both in blood and skin cells from
patient 6 together with a diploid chromosome 12 set (sample
6a and 6b).
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Table 1. Clinical data
Case n Age Sex Duration of disease Prior treatment Diagnosis1 TNM stage1
1 78 M 12 months NA T-MF IVB T3
2 92 F 11 months Topical nitrogen mustard T-MF IIB T3
3 67 F 12 months MTX, PCT T-MF with secondary SS IVA1 T4(3)
4 79 M 12 months MTX, PCT, RT T-MF IIB T3
5 85 M 12 months PCT T-SS after MF IVA2 T4
6 53 M 14 months Topical nitrogen mustard, PCT T-SS IVA1 T4
7 69 M 12 months NA T-MF IIB T3
8 63 M 3 months MTX T-MF IIB T3
9 82 F 4 years None T-MF IIB T3
10 77 F 20 months Topical nitrogen mustard T-MF IVA2 T3
11 78 M 4 years Topical nitrogen mustard, IFN T-MF IVB T3
12 79 M None None T-MF IIB T3
13 47 M 10 years IFN T-MF IIB T3
14 83 F 15 years None T-MF IIB T3
15 54 M 24 months Photopheresis T-MF IVB T4(3)
16 62 M 36 months None T-MF IIB T3
17 48 F 6 months IFN T-SS IVA1 T4(3)
18 85 M 3 months None T-SS IVA1 T4(3)
19 57 M 24 months MTX, Bexarotene, IFN, Vercyte Secondary SS with T-MF IVA2 T4(3)
20 73 M 48 months MTX, IFN, Bexarotene, PCT Secondary SS after MF IVA1 T4
21 83 M 12 months None SS IVA1 T4
22 80 M 3 months None SS IVA1 T4
23 70 M 6 months None SS IVA1 T4
24 82 F 6 months None SS IVA1 T4
1At the time of biological sampling.
F, female; M, male; MF, mycosis fungoides; MTX, methotrexate; NA, data not available; PCT, polychemotherapy; RT, radiotherapy; SS, Se´zary syndrome;
T-MF, transformed MF; TNM, tumor node metastasis; T-SS, transformed SS.
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Figure 1. Interphase FISH strategy to determine NAV3 locus structure. (a) Cytogenetic preparations allowed simultaneous triple hybridization with Spectrum
Green BAC 786A5 pericentromeric probe (shaded spots), Spectrum Red 50NAV3 probe BAC 781A6 (open spots), and DEAC 30NAV3 probe composed of
an equivalent mixture of BACs 136F16 and 36P3 (black spots). Expected profiles would be 2 Green (2G)/2 Fusion (2F) signals for normal diploid nucleus, 2G/1F
for NAV3 monoallelic deletion, 2G/1F/1 split for NAV3 breakpoint pattern. (b) Three consecutive dual-color dual-probe hybridizations on the same slide
(isolated nuclei or touch imprints) are as follows: first step—Spectrum Green BAC 786A5 pericentromeric probe together with Spectrum Red 50NAV3 probe
BAC 781A6; second step—Spectrum Green BAC 786A5 pericentromeric probe together with Spectrum Red 30NAV3 BACs 136F16 and 36P3 probes; third
step—Spectrum Green 50NAV3 probe BAC 781A6 with Spectrum Red 30NAV3 BACs 136F16 and 36P3. Expected profiles would be 2G/2R signals for normal
diploid nucleus, and 2G/1R for NAV3 monoallelic partial deletion for the first and second steps. For the third step, 2F signals were expected for normal nucleus
and 1F/1 split for NAV3 breakpoint.
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In blood sample 3a from case 3, a monoallelic deletion
involving the control pericentromeric signal was observed in
73% of diploid blood cells (Figure 2a).
CGH array interpretation and compilation together with
other cytogenetic data
Chromosome 12 CGH array profile was determined for 24
samples from 22 patients. Copy number changes were
determined by log2 fluorescence ratio using the Curie
Institute VAMP tool. Interestingly, 17 samples from 16
patients (cases 7–24) with a normal FISH pattern in our study
also displayed a normal chromosome 12 CGH array profile.
In patients with an abnormal FISH pattern (cases 1–6), CGH
array profiles (Figure 3) were both concordant and comple-
mentary to karyotype and FISH data as compiled for each
case. A skin sample from case 1 exhibited a global
chromosome 12 gain in accordance with the presence of
three balanced 50NAV3/12p and 30NAV3/12p FISH signals in
about 60% of nuclei. Ploidy could not be determined owing
to the lack of conventional cytogenetics, so chromosome 12
trisomy was retained as final interpretation. The skin sample
in case 2 displayed a normal CGH array profile. Four
balanced 50NAV3/12p and 30NAV3/12p FISH signals were
observed in about 40% of cells, suggesting chromosome 12
tetrasomy in a subclone. The balanced chromosome 12
profile may be due to the dilution of tetrasomic cells into
diploid cells and/or normalization of tumor DNA input and
signal ratios. Both blood and skin samples in case 3 exhibited
an imbalanced CGH array profile, showing a large 12q12pter
deletion in the blood sample and a whole chromosome 12
loss in the skin sample. The FISH data were concordant with
a diploid imbalanced pattern at the blood level as shown by
12p FISH signal loss in the context of t(X;12)(q23;q24)
translocation. At the skin level, the presence of three
balanced 50NAV3/12p and 30NAV3/12p FISH signals showed
chromosome 12 trisomy in hypotetraploid cells (metaphases
contained about 80 chromosomes). Detailed karyotype and
multi-FISH analyses of this case have been reported else-
where (Prochazkova et al., 2005). In case 4, the first skin
sample (2003) displayed an imbalanced CGH array profile
with a large 12p11qter loss. Accordingly, FISH experiments
showed the presence of three 50NAV3 and 30NAV3 signals in
about 36% nuclei with four 12 pericentromeric signals, as
observed for more than 50% of nuclei in the second skin
sample (2005). As DNA content analysis was in accordance
with hypotetraploidy (Prochazkova et al., 2007), our data
a b c d
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Figure 2. Interphase FISH. (a and b) Blood sample in case 3 with transformed mycosis fungoides. Triple hybridization on blood cell cytogenetic preparation.
(a) Spectrum Green BAC 786A5 pericentromeric probe and Spectrum Red 781A6 50NAV3 probe show a 1G/2R pattern on both metaphase and interphase
nuclei. (b) Colocalization of DEAC 136F16 and 36P3 30NAV3 probe signals as compared with the Spectrum Red 781A6 50NAV3 probe signals in Figure 2a.
Such a pattern indicates partial deletion of one pericentromeric region in 73% of diploid cells. Scale bar¼ 10mM. (c and d) Case 3: skin sample in case 3
with transformed mycosis fungoides. Triple hybridization on cytogenetic preparation of skin tumor cells. (c) 3R/3G pattern observed both on metaphase and
interphase nuclei (71%) with Spectrum Green BAC 786A5 pericentromeric probe and Spectrum Red 781A6 50NAV3 probe. (d) Same 3R/3G pattern with
colocalization of DEAC 136F16 and 36P3 30NAV3 probe signals as compared with the Spectrum Red BAC 781A6 50NAV3 probe on Figure 2c. Such a pattern
indicates chromosome 12 trisomy in hypotetraploid cells without NAV3 breakpoint or deletion. Scale bar¼ 10 mM. (e and f) Consecutive dual-color dual-probe
hybridization on frozen imprints from skin sample in case 2. (e) Spectrum Green BAC 786A5 pericentromeric probe together with Spectrum Red BAC 781A6
50NAV3 probe showing a 4G/4R pattern in 44% of nuclei. (f) Spectrum Green BAC 781A6 50NAV3 probe with Spectrum Red BACs 136F16 and 36P3 30NAV3
probes display colocalized 4F (37%) or 2F (57%) signals in accordance with the absence of NAV3 breakpoint. Such a pattern indicates chromosome 12
tetrasomy in hypotetraploid cells without NAV3 breakpoint or deletion. Scale bar¼ 10 mM. (g–i) Case 4: consecutive dual-color dual-probe hybridization on
isolated nuclei from formalin fixed skin sample (4a). (g) Spectrum Green BAC 786A5 pericentromeric probe together with Spectrum Red BAC 781A6 50NAV3
probe showing a 4G/3R pattern in 32% of nuclei. (h) Spectrum Green BAC 786A5 pericentromeric probe together with Spectrum Red BACs 136F16 and 36P3
30NAV3 probes display a 4G/3R pattern in 36% of nuclei. (i) Spectrum Green BAC 781A6 50NAV3 probe with Spectrum Red BACs 136F16 and 36P3 30NAV3
probes display colocalized 3F (36%) or 2F (53%) signals without NAV3 breakpoint. Such a pattern indicates chromosome 12 tetrasomy and 12p11qter
monoallelic deletion including NAV3. Scale bar¼ 10mM.
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suggested a large 12p11qter deletion involving NAV3 but not
the 12p pericentromeric region corresponding to the control
probe. Case 5 exhibited a limited gain on chromosome 12q
(enh 12q24.31–q24.32) that involved neither the NAV3 locus
nor the pericentromeric region, as also shown by balanced
50NAV3/12p and 30NAV3/12p FISH ratios. Chromosome 12
trisomy observed in about 50% of cells by FISH was present
in the context of hypotetraploidy as seen on the karyotype.
The blood sample of case 6 showed a normal chromosome
12 CGH array profile, whereas a 12q deletion involving
NAV3 was observed by FISH analysis in about 35% of cells
both from blood and skin. As this subclone did not account
for the majority of cells, a balanced CGH array profile was
found. Altogether, an abnormal number of chromosome 12
set was observed in six samples from five patients (samples 1,
2, 3b, 4a, 4b, and 5). Structural abnormalities of chromosome
12 with CGH array imbalances were observed in six samples
from four patients (samples 3a, 4a, 4b, 5, 6a and 6b). They
corresponded either to gains or losses on chromosome 12q
outside the NAV3 region (samples 3a and 5) or to a large 12q
deletion including NAV3 (samples 4a, 4b, 6a, and 6b). None
of these structural chromosome 12 abnormalities resulted in
either a specific loss of the NAV3 locus or a breakpoint within
the NAV3 gene. In total, the compilation of FISH and CGH
array data are summarized in Table 3.
DISCUSSION
The identification of a balanced translocation t(12;18)
(q21;q21.2) breakpoint on chromosome 12 in one patient
with SS led Karenko et al. (2005) to demonstrate that the
12q21.2 breakpoint disrupted the NAV3 gene. Using locus-
specific FISH probes covering the 30 part of the NAV3 gene
(exons 10–40) and a chromosome 12 centromeric probe as
control, they found loss of NAV3 signals in 50% of patients
with early MF (4/8) and in 85% of patients with advanced
MF/SS (11/13). Therefore, the NAV3 gene breakpoint has been
considered as the most recurrent cytogenetic abnormality of
CTCL playing a role in oncogenesis by haploinsufficiency
(Karenko et al., 2005; Sterry, 2007). In this study, we sought
the presence of this genetic breakpoint in an independent
series of 31 samples of advanced CTCL cases. We also
developed a break-apart FISH strategy to detect a specific
NAV3 breakpoint on different types of cytogenetic and
histological preparations. The main finding of our study is
the absence of NAV3 genetic breakpoint, as shown by the
absence of split signal between the 50NAV3 and 30NAV3
probes on 31 samples from 24 patients with advanced CTCL.
Accordingly, no partial NAV3 deletion was observed as
shown by similar ratios between either 50NAV3 or 30NAV3
probe and 12p control probe. These data were obtained with
the same BAC probes for 50NAV3 (781A6) and 30NAV3
Table 2. Biological data of patients with abnormal profile
FISH results
Case n (TNM) Sample 50NAV3/12p 30NAV3/12p
50NAV30/
30NAV3 CGH array profile Global interpretation
1. T-MF (IVB T3) Skin1 3/3: 62%
2/2: 32%
3/3: 55%
2/2: 41%
3F: 51%
2F: 46%
enh 12 Chromosome 12 trisomy
2. T-MF (IIB T3) Skin1 4/4: 44%
2/2: 56%
4/4: 34%
2/2 60%
4F: 37%
2F: 57%
No imbalance Chromosome 12 tetrasomy
3. T-MF with
secondary SS
(IVA1 T4(3))
(a) Blood2 2/1: 73%
2/2: 24%
2/1: 73%
2/2 24%
2F: 97% dim 12q12pter t(X;12)(q23;q24)with 12q12pter loss
(b) Skin2,3 3/3: 75%
2/2: 20%
3/3: 76%
2/2: 19%
3F: 69%
2F: 29%
dim 12 Hypotetraploidy and chromosome
12 trisomy
4. T-MF (IIB T3) (a) Skin3 2/2: 53%
3/4: 32%
2/2: 51%
3/4: 36%
2F: 53%
3F: 36%
dim 12p11qter Hypotetraploidy and 12p11qter loss
including NAV3
(b) Skin1 2/2: 36%
3/4: 50%
2/2: 35%
3/4: 58%
2F: 32%
3F: 58%
ND Hypotetraploidy and 12p11qter loss
including NAV3
5. T-SS after MF
(IVA2 T4)
Blood2 3/3: 52%
2/2: 46%
3/3: 52%
2/2: 46%
3F: 52%
2F: 46%
enh 12q24.31–
q24.32
Hypotetraploidy and chrom. 12 trisomy
with imbalances
6. T-SS (IVA1 T4) (a) Blood2 2/2: 52%
1/2: 37%
2/2: 52%
1/2: 37%
2F: 52%
1F: 37%
No imbalance 12q deletion including NAV3
(b) Skin1,2 2/2: 69%
1/2: 31%
2/2: 66%
1/2: 34%
2F: 62%
1F: 32%
ND 12q deletion including NAV3
1Fresh/frozen tissue imprints.
2Cytogenetic pellet.
3Isolated nuclei from formalin-fixed, paraffin-embedded tissue.
F, fusion; FISH, fluorescence in situ hybridization; ND, not done, MF, mycosis fungoides; SS, Se´zary syndrome; T-MF, transformed MF; SS, Se´zary syndrome;
TNM, tumor node metastasis; T-SS, transformed SS.
The score of an abnormal or variant pattern below 5% is not indicated, so the total score is not 100%. The sum of all variant patterns was usually less than
10%.
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(136F16 and 36P3), as those used by Karenko et al. (2005).
However, the NAV3 breakpoint with split signal between
50NAV3 and 30NAV3 probes has been identified to date in
only one patient (case 3 in the study of Karenko et al.) who
displayed t(12;18)(q21;q21.2) (Karenko et al., 2005). In other
cases, they used the same 30NAV3 probes as in our study
(BACs 136F16 and 36P3) together with a centromeric control
probe that cannot preclude a specific breakpoint within the
NAV3 gene. As seen on metaphases of Figure 2, both sister
chromatids of each chromosome may provide a small
separation of each locus-specific signals whose number
may be difficult to determine on interphase nuclei, especially
in dividing hypotetraploid cells. Moreover, we analyzed
whole nuclei obtained from imprints or fixed material by
interphase FISH to avoid nuclei truncation and a false
diagnosis of deletion (Belaud-Rotureau et al., 2006, 2007).
Finally, we also found a complete concordance between
FISH analyses of metaphases and on interphase nuclei from
the same samples.
Another major finding of our series is that the 12q deletion
including the NAV3 gene is a rare event in advanced CTCL
(2 out of 24 patients). Such a result was obtained both by FISH
and CGH arrays for 22 patients and also by multicolor FISH
on tumor cell metaphases in some patients (data not shown).
As in cases 1 and 2 with large chromosome 12 deletions in
the study of Karenko et al. (2005), we also observed two
Case 1
Case 2 12
12
12
12
12
12
12
Case 4
Case 5
Case 6
Case 3 skin
Case 3 blood
0.3
0.0
–0.3
–0.6
0.3
0.0
–0.3
–0.6
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0.3
0.0
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CEN NAV3
Figure 3. Chromosome 12 profile. CGH array profiles obtained through the VAMP graphical tool (http://bioinfo-out.curie.fr/CAPweb/) after co-hybridization
of tumoral and control DNA. These graphs represent the log2 ratio of the fluorescence intensities along chromosome 12. Gains appear in red, losses in green,
and balanced signals in yellow. The blue bar and the black landmark indicate NAV3 locus and centromere positions, respectively.
Table 3. Compilation of chromosome 12 analysis by different techniques
Samples
n=31
Chromosome
12 ploidy
12q deletion
with NAV3 loss
NAV3
breakpoint 12p deletion
Other
imbalance
23 Disomy 0 0 0 0
2 Disomy Case 6: 1 blood and
1 skin samples
0 0 0
6 Tetrasomy
or trisomy
Case 4: 2
skin samples
0 Case 3: 1 blood
sample
Case 5: 1 blood
sample
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patients (cases 4 and 6) with a large 12q deletion including
the NAV3 locus, as confirmed by CGH array analysis of the
skin sample in case 4 and the blood cell metaphases in case
6. Studying two independent samples for each patient also
provided concordant data. Only one case in our study (case 3
blood sample) provided evidence of partial chromosome 12
loss outside 12q21 on the basis of the presence of a
t(X;12)(q23;q24), whereas case 5 displayed on CGH array
analysis, 12q gain outside the 12q21 and NAV3 locus. The
inclusion of cases with advanced disease is unlikely to
account for our negative results, as 12q deletion with loss of
30NAV3 signals was observed in 85% of advanced MF/SS
patients by Karenko et al. (2005). Moreover, we also included
seven cases before any treatment (cases 9, 12, 14, and
21–24), four of them presenting de novo SS. Finally, copy
number variations, such as insertion and deletion could
explain genetic polymorphisms and have been identified on
chromosome 12 (Mills et al., 2006). However, the allelic
frequencies of insertion and deletions would not account for
the high rate of NAV3 deletion detection (85%) by Karenko
et al. (2005). Moreover, the usual small size of nucleotidic
variations (single base, repeat expansions, or other insertion
and deletions o100bp in length) will not allow their
detection by large BAC probe hybridizations performed in
both studies. Such polymorphisms would, however, require
careful interpretation and control of CGH array data obtained
with oligonucleotidic probes.
Our results are also in broad accordance with our previous
CGH study of 11 T-MF patients (Prochazkova et al., 2007)
and those obtained by Mao et al. (2002) on an unselected set
of 18 patients with SS and 16 patients with MF. Another CGH
study of 32 patients with CTCL identified the pattern dim6q-
enh7-enh8-dim13 as the most frequent combination of
chromosomal imbalances, and a higher number of chromo-
somal imbalance was found associated with shorter survival
(Fischer et al., 2004). It is unlikely that large 12q deletion
including 12q21 would not have been detected by CGH
array in these series and in our present CGH array analysis.
Another cytogenetic study of 28 SS cases by multicolor FISH
and CGH as well as a literature survey of 274 SS karyotypes did
not identify chromosome 12 as being commonly involved in
losses, as opposed to 1p, 10/10q, 17p, 19, or recurrent
translocation (Mao et al., 2003). Interestingly, conventional
cytogenetics showed an abnormal complex karyotype in 12 out
of 28 patients involving chromosomes 1 and 17 (68%) or
chromosomes 10 and 14 (42%). Multicolor molecular cytoge-
netics (SKY) of 19 blood samples fromMF/SS patients also found
complex karyotypes and neither 12q deletion nor translocation
was identified (Batista et al., 2006).
More recently, SKY analysis of cell lines obtained from
skin biopsies in four patients in 1999 was compared with the
analysis of three new skin cell lines obtained in 2001 (Padilla-
Nash et al., 2007). The finding that most cytogenetic changes
did not follow a consistent pattern in at least two out of three
patients was found indicative of a general genetic instability
possibly linked to the inhibition of DNA repair mechanisms
(Padilla-Nash et al., 2007). Although speculative, such a
hypothesis would provide a general explanation for the
complexity of CTCL karyotypes and the lack of a primary
cytogenetic event in MF and SS pathogenesis. Indeed, we
also reported that several cytogenetic subclones may evolve
from a common T-cell monoclonal population in a patient
with MF during transformation (Prochazkova et al., 2005).
Chromosomal imbalances, aneuploidy, and/or tetraploidiza-
tion were also found in a limited series of patients with
advanced MF/SS (Prochazkova et al., 2007). Individual
exposure to different genotraumatic mechanisms together with
geographic or ethnical variation may indeed account for
different secondary chromosomal changes observed between
series. Chromosomal instability and aneuploidy have been
found to play an important role in the pathogenesis and
prognosis of different cancer subtypes bearing a common
expression signature (Carter et al., 2006). The identification of
CTCL with genetic instability, together with the identification of
allelic loss or epigenetic silencing of tumor suppressor genes
(van Doorn et al., 2005), would help to identify patients with
MF who will progress to an advanced stage with poor prognosis.
MATERIALS AND METHODS
Case selection
To investigate samples with a high tumor cell content, we retrieved
from our files 24 patients with epidermotropic CTCL and advanced
clinical TNM stage at the time of sampling (Olsen et al., 2007). The
study was approved by the medical ethical committee of the
University Hospital of Bordeaux after patients informed consent,
according to the guidelines of the French Bioethical law and the
Institut National contre le Cancer (INCA). The study was also
conducted according to the Declaration of Helsinki Principles. As
shown in Table 1, 15 patients presented at the time of the study with
T-MF based on the presence of tumor (T3 stage) and a dense dermal
infiltrate (above 50% of skin cells) with more than 25% of large
tumor cells (Vergier et al., 2000). Two of the 15 T-MF cases (cases 3
and 19) and one patient with MF (case 20) had secondary SS (Olsen
et al., 2007) characterized by erythroderma (T4 stage) and high
blood tumor burden (B2 stage) without blood large-cell transforma-
tion as documented for case 3 (Prochazkova et al., 2005). In four
other patients with either a history of SS (cases 6, 17, and 18) or MF
(case 5), large-cell transformation was observed only at the blood
level together with leukemic spreading and erythroderma, thereafter
called transformed SS.
Four patients with typical SS (cases 21–24) had an elevated
peripheral blood lymphocyte count (above 10,000 cells per ml) with
atypical cells with hyperconvoluted cerebriform nuclei (at least
above 1,000 cells per ml). Finally, we included 31 samples
corresponding to skin (n¼ 18), blood (n¼ 11), lymph node (n¼ 1),
and spleen (n¼ 1) material.
Cell culture and metaphase spread
In nine patients (cases 5, 6, 18–24) with SS or transformed SS and in
one patient with T-MF associated with SS (case 3), the presence of an
elevated lymphocyte count (above 10,000 cells/ml) with hypercon-
voluted cerebriform nuclei (at least above 1,000 cells/ml) prompted
us to culture blood cells according to the standard protocol (Mao
et al., 2003). In three patients with T-MF or transformed SS (cases 3,
6, and 18), cells dissociated from skin tumors were cultured for
72 hours according to our published protocol (Chevret et al., 2006).
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Locus-specific FISH methodology
Frozen skin touch imprints or nuclei preparation from formalin-fixed,
paraffin-embedded (FFPE) material were obtained and hybridized
according to our established protocols (Belaud-Rotureau et al., 2006,
2007).
To cover the NAV3 gene locus, the same set of BAC probes
(781A6, 494K17, 136F16, 36P3) as in Karenko et al. (2005) was
obtained from the RPCI-11 library through Invitrogen (Cergy-
Pontoise, France). A 12p11.22 pericentromeric probe (RP11-
786A5; gift from Dr Rocchi, www.biologia.uniba.it/rmc/) was used
as control probe. The BACs were amplified and DNA probes were
isolated using the Plasmid Maxi Kit (Qiagen, Courtaboeuf, France).
Probe validation included hybridization on healthy donor meta-
phases and sequencing their 50 and 30 ends using consensus primers
and verification with the Blast Program of the National Center for
Biotechnology Information (NCBI) (http://ncbi.nlm.nih.gov/blast).
These controls led us to discard the BAC 494K17 probe that was
not found free of contaminants despite several deliveries from the
supplier (data not shown). All probes were labeled with appropriate
fluorochromes using a nick translation kit (Abbott-Vysis, Voisins le
Bretonneux, France) All FISH patterns were recorded by analyzing
100 non-overlapped nuclei by two independent observers (MM and
MP), and a mean score pattern was determined.
On cytogenetic preparations, a simultaneous triple co-hybridiza-
tion was performed with the combination of Spectrum Green BAC
786A5 pericentromeric probe, Spectrum Red 50NAV3 probe BAC
781A6, and DEAC (Blue) 30NAV3 probe composed of an equivalent
mixture of BACs 136F16 and 36P3 (Figure 1a). In the absence of
genetic breakpoint, the 50NAV3 and 30NAV3 probes provided
colocalized signals both on metaphase and interphase preparations.
Together with the pericentromeric probe, a 2 Green/2 Fusion (2G/
2F) signal pattern was observed for normal nuclei (Figure 1a). In case
of NAV3 monoallelic deletion, a 2G/1F pattern was expected for
diploid cells. In case of a NAV3 breakpoint, a 2G/1F/1Red (R)/1Blue
(B) pattern was expected.
On nuclei extracted from FFPE material or frozen touch imprints,
the DEAC signal was not strong enough above the nucleus
background to allow simultaneous triple hybridization. Therefore,
we performed three consecutive dual-color dual-probe hybridiza-
tions on these samples with microscopic analysis between each step.
After analysis, coverslips were removed and slides were washed by
phosphate-buffered saline for 5minutes, 2XSSC/Formamide 70% at
73 1C for 3minutes followed by dehydration in graded ethanol baths
before a new hybridization step. The absence of remaining signal
was checked before rehybridization.
We first used a combination of Spectrum Green BAC 786A5 12p
pericentromeric probe together with Spectrum Red 50NAV3 probe
BAC 781A6, followed by Spectrum Green BAC 786A5 pericentro-
meric probe together with Spectrum Red 30NAV3 BACs 136F16 and
36P3 probes, and finally Spectrum Green 50NAV3 probe BAC 781A6
with Spectrum Red 30NAV3 BACs 136F16 and 36P3 (Figure 1b). In
diploid cells, detection of either 50NAV3 or 30NAV3 signals together
with the control probe signals provided a typical 2R/2G balanced
pattern and a 1R/2G or 2R/1G pattern in case of hemizygous
deletion (Figure 1b). However, hyperdiploid or hypotetraploid
subclones were observed in some tumors. For example, a balanced
variant pattern (3/3, 4/4) or an imbalanced variant pattern (2/3, 3/2,
4/3, 3/4, and so on) was observed. After hybridization of 50NAV3
and 30NAV3 probes, the normal diploid pattern was 2F, whereas the
breakpoint of NAV3 would theoretically provide a typical 1F/1R/1G
pattern. A partial NAV3 deletion would give a 1F/1R/0G or 1F/0R/1G
pattern. All individual patterns were scored and taken into account
when their individual percentage exceeded a 5% threshold. The sum
of all variant patterns did not usually exceed a 10% threshold.
CGH array profile of chromosome 12
Tumor DNA was extracted from fresh frozen skin biopsies grossly
dissected to select tumor cell-rich areas with massive dermal
infiltrates or from total peripheral blood samples. Control DNA
was prepared from a pool of peripheral blood samples of healthy
donors.
CGH analysis of three cases (cases 3, 4, and 7) was previously
reported (Prochazkova et al., 2007). According to standard
procedures (Orsetti et al., 2006), tumor and control DNA (600 ng
each) were co-hybridized on a 3113-BAC Integrachip array
produced by IntegraGen (Evry, France) and obtained through
ArrayGenomics (Voisins le Bretonneux, France). This BAC array
has 1Mb resolution and contains 176 BAC clones mapping to
chromosome 12. Specific BAC probes covering the NAV3 gene
(position 76749328–77130921) are not present on this array, but the
NAV3 locus is flanked by BAC clones (DBACA14ZG11V and RP11-
530C5) at a distance of 179 kb and 1.4Mb, respectively. Hybridiza-
tion, scanning, normalization, and data analysis were performed at
the Bergonie´ Institute CGH array facility using GenepixPro 4.0
(Molecular Devices, St Gre´goire, France). Files were normalized
using the Curie Institute VAMP tool (La Rosa et al., 2006) through the
CAPweb bioinformatics platform (Liva et al., 2006) (http://bioinfo-
out.curie.fr/CAPweb/). Analyses were retained if more than 90% of
BAC clones presented a good signal-to-noise ratio (SNR of at least 3).
Each clone has four replicates and clones with poor consistency or
with only one aberrant value were discarded.
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